Exacerbation of adult-onset Still's disease, possibly related to elevation of serum tumor necrosis factor-alpha after etanercept administration

Int J Rheum Dis. 2010 Oct;13(4):e67-9. doi: 10.1111/j.1756-185X.2010.01544.x.

Abstract

Adult-onset Still's disease (AOSD) is a systemic inflammatory disease of unknown etiology. A 44-year-old male patient presented with AOSD complicated by macrophage activation syndrome after etanercept therapy. His serum tumor necrosis factor-α (TNF-α) level was increased dramatically after etanercept therapy. The clinical course of this case suggests that the increased TNF-α level by etanercept administration might cause macrophage activation syndrome in this case.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antirheumatic Agents / adverse effects*
  • Etanercept
  • Glucocorticoids / administration & dosage
  • Humans
  • Immunoglobulin G / adverse effects*
  • Immunoglobulins, Intravenous / administration & dosage
  • Inflammation Mediators / blood*
  • Macrophage Activation Syndrome / chemically induced*
  • Macrophage Activation Syndrome / immunology
  • Macrophage Activation Syndrome / therapy
  • Male
  • Methylprednisolone / administration & dosage
  • Plasma Exchange
  • Pulse Therapy, Drug
  • Receptors, Tumor Necrosis Factor
  • Still's Disease, Adult-Onset / drug therapy*
  • Still's Disease, Adult-Onset / immunology
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / blood*
  • Up-Regulation

Substances

  • Antirheumatic Agents
  • Glucocorticoids
  • Immunoglobulin G
  • Immunoglobulins, Intravenous
  • Inflammation Mediators
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Etanercept
  • Methylprednisolone